Dr. Lal PathLabs reports a 10.6% increase in revenue, reaching ₹660 Cr in Q3 FY26. EBITDA (before exceptional items) increased by 16.3% with a margin of 27.2%. The company’s PAT stood at ₹91 Cr with a margin of 13.9%. An interim dividend of ₹3.5 per share has been declared for Q3 FY26.
Financial Performance
Dr Lal PathLabs announced its financial results for the quarter ended December 31, 2025, showcasing significant growth across key metrics:
- Revenue: Increased by 10.6% to ₹660 Cr in Q3 FY26, and by 10.8% for the nine months ended December 2025.
- EBITDA (before exceptional items): Increased by 16.3%, resulting in a margin of 27.2%.
- PAT: Recorded at ₹91 Cr with a margin of 13.9%.
The results include an exceptional impact of ₹30.1 Cr on account of Labour codes.
Dividend Announcement
The company has declared an interim dividend of ₹3.5 per share for Q3 FY26.
Balance Sheet Highlights
As of December 31, 2025, the company’s cash and bank balances stood at ₹1,411 Cr.
Detailed Financial Overview (₹ Cr)
| Particulars | FY26 | FY25 | Gr % | FY26 | FY25 | Gr % |
|---|---|---|---|---|---|---|
| Revenue | 660 | 597 | 10.6% | 2060 | 1859 | 10.8% |
| Material consumed | 129 | 117 | 399 | 364 | ||
| Employee benefit Expenses | 135 | 126 | 399 | 367 | ||
| Fees to collection centers | 96 | 87 | 294 | 264 | ||
| Other Expenses | 121 | 112 | 372 | 337 | ||
| EBITDA before exceptional item | 179 | 154 | 16.3% | 596 | 527 | 13.1% |
| Statutory impact of new Labour Codes | 30 | 0 | 30 | 0 | ||
| EBITDA | 149 | 154 | -3.2% | 566 | 527 | 7.4% |
| Other Income | 24 | 25 | 77 | 68 | ||
| Depreciation Cost | 42 | 36 | 117 | 106 | ||
| Finance Cost | 7 | 5 | 17 | 17 | ||
| PBT | 124 | 138 | -10.1% | 509 | 471 | 8.0% |
| PAT | 91 | 98 | -6.8% | 378 | 337 | 12.2% |
| EPS | 5.4 | 5.8 | -6.6% | 22.4 | 20.0 | 12.2% |
Source: BSE
